CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
Author:
Affiliation:
1. Department of Oncology and Metabolism Medical School University of Sheffield Sheffield UK
2. Weston Park Hospital Whitham Road Sheffield UK
Publisher
Wiley
Subject
General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/mco2.97
Reference134 articles.
1. Global Cancer Statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung H;CA Cancer J Clin,2021
2. Molecular profiling for breast cancer: a comprehensive review;Kittaneh M;Biomark Cancer,2013
3. Mechanisms of Endocrine Resistance in Breast Cancer
4. CDK4/6 inhibitors in breast cancer – from in vitro models to clinical trials
5. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Mass Spectrometry-Based Proteomics for Classification and Treatment Optimisation of Triple Negative Breast Cancer;Journal of Personalized Medicine;2024-09-05
2. Recent Advances in Immunotherapy and Targeted Therapy of Triple Negative Breast Cancer;Current Pharmaceutical Biotechnology;2024-07-31
3. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies;Frontiers in Oncology;2024-05-28
4. Microbiota enterotoxigenic Bacteroides fragilis-secreted BFT-1 promotes breast cancer cell stemness and chemoresistance through its functional receptor NOD1;Protein & Cell;2024-03-04
5. Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment;Molecules;2023-11-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3